Research Analysts Set Expectations for TSE:GUD Q1 Earnings

Knight Therapeutics Inc. (TSE:GUD) – Research analysts at Stifel Canada issued their Q1 2025 EPS estimates for shares of Knight Therapeutics in a research note issued on Monday, March 24th. Stifel Canada analyst J. Keywood expects that the company will post earnings of $0.03 per share for the quarter. The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.10 per share. Stifel Canada also issued estimates for Knight Therapeutics’ Q3 2025 earnings at $0.06 EPS, Q4 2025 earnings at $0.04 EPS and FY2026 earnings at $0.21 EPS.

Several other research firms have also recently issued reports on GUD. Canaccord Genuity Group cut Knight Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 21st. Stifel Nicolaus increased their price objective on shares of Knight Therapeutics from C$6.25 to C$7.45 and gave the company a “buy” rating in a report on Tuesday. Finally, Research Capitl raised shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 11th. One investment analyst has rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of C$7.48.

Knight Therapeutics Price Performance

TSE:GUD opened at C$6.09 on Thursday. The business’s 50-day simple moving average is C$5.74 and its two-hundred day simple moving average is C$5.60. Knight Therapeutics has a 52 week low of C$5.09 and a 52 week high of C$6.45. The stock has a market cap of C$616.00 million, a PE ratio of -20.33, a P/E/G ratio of -1,013.50 and a beta of 0.50. The company has a quick ratio of 1.79, a current ratio of 3.36 and a debt-to-equity ratio of 7.52.

Insider Activity at Knight Therapeutics

In other Knight Therapeutics news, insider Sime Armoyan purchased 17,600 shares of Knight Therapeutics stock in a transaction that occurred on Tuesday, March 4th. The shares were bought at an average price of C$5.48 per share, for a total transaction of C$96,488.48. Over the last three months, insiders sold 3,143,300 shares of company stock valued at $19,733,740. Insiders own 45.62% of the company’s stock.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.